Importation and Innovation
25 Pages Posted: 2 Oct 2006 Last revised: 7 Oct 2022
Date Written: September 2006
Abstract
Importation of drugs into the U.S. would result in a decline in U.S. drug prices. The purpose of this paper is to assess the consequences of importation for new drug development. A simple theoretical model of drug development suggests that the elasticity of innovation with respect to the expected price of drugs should be at least as great as the elasticity of innovation with respect to expected market size (disease incidence). I examine the cross-sectional relationship between pharmaceutical innovation and market size among a set of diseases (different types of cancer) exhibiting substantial exogenous variation in expected market size. I analyze two different measures of pharmaceutical innovation: the number of distinct chemotherapy regimens for treating a cancer site, and the number of articles published in scientific journals pertaining to drug therapy for that cancer site. Both analyses indicate that the amount of pharmaceutical innovation increases with disease incidence. The elasticity of the number of chemotherapy regimens with respect to the number of cases is 0.53. The elasticity of MEDLINE drug cites with respect to cancer incidence throughout the world is 0.60. In the long run, a 10% decline in drug prices would therefore be likely to cause at least a 5-6% decline in pharmaceutical innovation.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Pharmaceutical Innovation, Mortality Reduction, and Economic Growth
-
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
-
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
-
Managed Care, Drug Benefits and Mortality: An Analysis of the Elderly
-
"Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer Welfare
By James W. Hughes, Michael J. Moore, ...
-
The Cost of Us Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions
By Thomas A. Abbott and John A. Vernon
-
Intellectual Property and Marketing
By Darius N. Lakdawalla, Tomas Philipson, ...
-
The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output